Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
In this study a mistletoe preparation (Iscador Qu) is added to standard therapy in inoperable
pancreatic cancer in order to evaluate effect on overall survival and health-related quality
of life. Half of participants will take subcutaneous injections with mistletoe in addition to
standard therapy (palliative chemotherapy or best supportive care); the other half will
receive a placebo and standard therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Karolinska University Hospital
Collaborators:
Cancerforskningsfonden i Norrland Dagmar Ferbs Minnesfond Ekhagastiftelsen Immunpathologisches Labor, University Tübingen Karolinska Institutet Regional Cancer Centre Stockholm Gotland Signe & Ane Gyllenbergs Stiftelse Stiftelsen Konung Gustaf V:s Jubileumsfond för cancerforskning The Sjöberg Foundation University of Witten/Herdecke